1. What data in particular will be shared?
   Response - All of the individual participant data collected during the trial, after de-identification.
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Informed Consent Form
   
   
3. Who will be able to view these files?
   Response - Researchers who provide a methodologically sound proposal.
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response (Others) -  Proposals should be directed to email- anjali.kumari@kims.ac.in with proper reason.


6. For how long will this data be available start date provided 02-01-1970 and end date provided 02-01-1970?
   Response - Beginning 3 months and ending 5 years following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

Carpal tunnel syndrome (CTS) is the most prevalent entrapment neuropathy, caused by compression of the median nerve beneath the transverse carpal ligament at the wrist. Thickening and fibrosis of the subsynovial connective tissue (SSCT) contribute to restricted movement of the median nerve within the carpal tunnel. Cadaveric studies have shown that hydrodissection decreases gliding resistance of the median nerve by mechanically releasing these adhesions.

Standard non-surgical management includes wrist splinting, NSAIDs, activity modification, local corticosteroid injections, and physiotherapy. Recently, ultrasound-guided hydrodissection has emerged as a minimally invasive intervention in which targeted fluid injection (normal saline, D5W, platelet-rich plasma, hyaluronic acid) is used to physically separate the median nerve from the SSCT and flexor retinaculum, reducing compression and restoring nerve mobility. The injectate creates a perineural plane, mechanically loosening adhesions and improving nerve gliding.

A 2021 systematic review of randomised trials concluded that ultrasound-guided hydrodissection is safe and potentially effective for CTS but emphasised that optimal parameters like injectate type, volume, and frequency, remain undefined. A 2024 network meta-analysis found that D5W produced the most consistent improvement in symptoms and function at 4, 12, and 24 weeks.

Despite this growing body of research, no high-quality studies have directly compared single-injection with multiple-injection (“double-injection”) hydrodissection protocols. Given that adhesions may reform between sessions, repeated hydrodissection could theoretically yield more durable symptom relief. This evidence gap provides the rationale for the present study, which aims to compare the clinical and functional outcomes of double-injection versus single-injection ultrasound-guided hydrodissection in mild to moderate CTS.